Development

Key challenges posed to autologous and allogeneic treatments could be resolved by in-vivo CAR-T gene therapies.

Webinar Date/Time: Wed, Mar 1, 2023 11:00 AM EST

In the coming year, pharmaceutical innovation will be fueled by key trends throughout the quality sector.

The COVID-19 pandemic helped to showcase RNA molecules and their therapeutic potential. There were also lessons learned in terms of drug delivery, manufacturing, logistics, and storage.

Webinar Date/Time: Tue, Feb 28, 2023 2:00 PM EST

Webinar Date/Time: Thu, Feb 23, 2023 11:00 AM EST

Webinar Date/Time: Session 1: Evaluating the Best Formulations for Amorphous Solid Dispersions by Spray Drying: Tuesday, February 28th, 2023 4:00pm GMT | 11:00 am EDT | 5:00 pm CEST Session 2: ASDs by Spray Drying: Process Development & Scale-Up: Wednesday, March 22nd, 2023 at 4pm GMT | 11am EDT | 5pm CEST Session 3: Commercial Reality and Lifecycle Management of ASDs: Thursday, April 20th, 2023 at 4 GMT | 11am EDT | 5pm CEST

Webinar Date/Time: Tuesday, February 28th, 2023 at 11am EST | 8am PST | 4pm GMT | 5pm CET

Topical eye treatments can be beneficial for patients with a growing array of eye diseases, but only if taken appropriately.

Shifting guidance and the growing prominence of computer software assurance exemplify the state of computer software validation.

In vivo CAR-T gene therapies could resolve challenges faced by autologous and allogeneic treatments.

This new pioneering phase of mRNA is loaded with potential, but also obstacles and false dawns.

This event is now available on-demand!

Webinar Date/Time: Tuesday, February 21st, 2023 at 11am EST | 8am PST | 4pm GMT | 5pm CET

Recently, 2seventy bio announced the initiation of a strategic partnership with JW Therapeutics aiming at the collaboration being the development of 2seventy bio’s MAGE-A4 cell therapy in mainland China, Hong Kong, and Macao.

Webinar Date/Time: Tue, Jan 31, 2023 11:00 AM EST

This self-emulsifying system improves the miscibility and dispersibility of formulations in aqueous environments and may improve API solubility.

Advancing the use of AI to understand the whole of a disease can reveal drug development insights that lead to drug discovery breakthroughs.

This compilation allows readers to adjust their thinking to appreciate the full impact certain select technologies will make on the industry by 2026.

Inhaled vaccines must resist degradation and penetrate the mucosal lining in the airways and lungs.

Cell and gene therapies is unequivocally viewed as the biggest opportunity in the bio/pharma space.

Sosei Heptares and Eli Lilly have entered a multi-target collaboration and license agreement in diabetes and metabolic diseases.

GSK and Wave Life Sciences have entered into a collaboration to drive drug discovery and development for novel genetic targets.

AbCellera and Rallybio are teaming up to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases.

Emmes’ new facility is designed to support clients conducting cell and gene therapy research worldwide.

Generate Biomedicines published a preprint describing technology that can generate novel proteins towards desired functional or other properties.

In this episode of the Drug Solutions Podcast, Chris Spivey interviews executives at Shabas Solutions LLC, who ran the overseas QMM pilot project.

Advancing digital transformation can significantly reduce R&D costs and shorten drug discovery timelines.

Unique solutions are required to protect inherently unstable messenger RNA.

Although well known in R&D, PK/PD studies are an equally powerful tool for promoting successful biologic drug development.